Welcome to What's it Worth - a BONUS episode! Join your host Dr. Diana Langworthy and a come-back by P4 student co-host Garrison Griest as we get the scoop on poop! Our expert guest for this episode is Dr. Jen Ross, Antimicrobial Stewardship Clinical Pharmacist at M Health Fairview East and West Bank Hospitals. We're discussing a trial that evaluated the efficacy of a new orally administered fecal microbiota transplant capsule - SER-109.  This episode coincides with a Journal Club assignment that students in my Evidence Based Practice course completed last week - Hello PHAR6782 Students! Great work on your first official Journal Clubs! Key Points C. Difficile infections are a public health concern and put a heavy burden on the health care system Patients experiencing recurrent infections often are subject to expensive and/or prolonged antibiotic regimens with an option for site specific fecal microbiota transplant (FMT) at the discretion of their gastroenterologist SER-109 (VOWST) is an orally administered FMT that is intended to be standardized for commercial development that demonstrated a reduction in recurrent C. Diff rates and early re-engraftment of a healthy microbiome What populations are best to analyze for efficacy and safety in this Phase III RCT? ---> Tune in to find out! Erratum: Garrison mention's that patients on prednisone 20mg/day or more were excluded - this was an exclusion criteria for the Rebyota(R) trial and NOT the SER-109 VOWST trial. As it related to immunosuppressed patients, the SER-109 (VOWST) trial excluded:  1) Absolute neutrophil count of

Ver todos los episodios